XTX Topco Ltd Invests $59,000 in Genelux Co. (NASDAQ:GNLX)

XTX Topco Ltd acquired a new stake in Genelux Co. (NASDAQ:GNLX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,693 shares of the company’s stock, valued at approximately $59,000. XTX Topco Ltd owned about 0.07% of Genelux as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AMG National Trust Bank raised its holdings in shares of Genelux by 49.7% during the second quarter. AMG National Trust Bank now owns 75,351 shares of the company’s stock worth $147,000 after purchasing an additional 25,000 shares during the period. Highbridge Capital Management LLC bought a new position in Genelux in the second quarter worth about $1,231,000. Cubist Systematic Strategies LLC acquired a new position in Genelux in the second quarter valued at approximately $56,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Genelux during the second quarter valued at approximately $39,000. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Genelux during the 2nd quarter worth approximately $195,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Stock Performance

NASDAQ GNLX opened at $2.27 on Monday. Genelux Co. has a 1 year low of $1.60 and a 1 year high of $16.60. The stock has a market capitalization of $78.40 million, a P/E ratio of -2.39 and a beta of -2.05. The business’s fifty day moving average is $2.72 and its two-hundred day moving average is $2.41.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on GNLX shares. HC Wainwright dropped their target price on Genelux from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Roth Mkm began coverage on shares of Genelux in a research report on Tuesday, August 27th. They issued a “buy” rating and a $10.00 price objective on the stock. Guggenheim assumed coverage on Genelux in a research report on Tuesday, October 29th. They set a “buy” rating and a $8.00 price objective for the company. Finally, Roth Capital raised Genelux to a “strong-buy” rating in a research note on Tuesday, August 27th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $18.25.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.